A case report of successful treatment with immunoadsorption onto protein a in mixed connective tissue disease in childhood

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 4, 2008, Pages 337-342

  Rummler, Silke ^a,b   Althaus, Karina ^b   Maak, Bernhard ^c   Barz, Dagmar ^b  

^a University Hospital ^*  (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c Pediatric Department   (Germany)

Author keywords

Apheresis; Immunoadsorption; Mixed connective tissue disease; Protein A; Pulmonary arterial hypertension

Indexed keywords

BOSENTAN; COLCHICINE; CORTISONE; IMMUNOGLOBULIN; METILDIGOXIN; NIFEDIPINE; PHENPROCOUMON; PROTEIN A; SPIRONOLACTONE;

ARTHRITIS; ARTICLE; CASE REPORT; COMORBIDITY; HEART FAILURE; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MALE; MIXED CONNECTIVE TISSUE DISEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REMISSION; SCHOOL CHILD; SKIN ULCER; STEROID THERAPY;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; CHILD; COMBINED MODALITY THERAPY; CORTISONE; HUMANS; IMMUNOSORBENT TECHNIQUES; MALE; MIXED CONNECTIVE TISSUE DISEASE; REMISSION INDUCTION; STAPHYLOCOCCAL PROTEIN A; SULFONAMIDES;

EID: 49249100958     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00597.x     Document Type: Article

References (23)

1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med 1972 52: 148 59.
2. Soriano ER, McHugh NJ. Overlap syndromes in adults and children. In: Maddison JP, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology. Oxford: Oxford University Press, 1998 5.12, 1413 32.
3. Végh J, Soós G, Csipo I et al. Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost. Rheumatol Int 2006 26: 264 9.
4. Rech J, Kallert S, Hueber AJ, Requadt C, Kalden JR, Schulze-Koops H. Combination of immunoadsorption and CD20 antibody therapy in a patient with mixed connective tissue disease. Rheumatology 2006 45: 490 1.
5. Gensch K, Gudowius S, Niehues T, Kuhn A. Kollagenosen im Kindesalter. Hautarzt 2005 56: 925 36.
6. Michels H. Course of mixed connective tissue disease in children. Ann Med 1997 29: 359 64.
7. Bodolay E, Szekanecz Z, Devenyi K et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology 2005 44: 656 61.
8. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-term outcome in mixed connective tissue disease. Arthritis Rheum 1999 42: 899 909.
9. Nishimaki T, Aotsuka S, Kondo H. Immunological analysis of pulmonary hypertension in connective tissue disease. J Rheumatol 1999 26: 2357 62.
10. Ozawa T, Ninomiya Y, Honma T et al. Increased serum angiotensin I-Converting enzyme in patients with mixed connective tissue disease and pulmonary hypertension. Scand J Rheumatol 1995 24: 38 43.
11. Chen CH, Chen HA, Wang HP, Liao HT, Chou CT, Huang DF. Pulmonary arterial hypertension in autoimmune diseases: an analysis of 19 cases from a medical center in northern Taiwan. J Microbiol Immunol Infect 2006 39: 162 8.
12. Dequecker J, Geusens P, Wielands L. Short and long-term experience with plasmapheresis in connective tissue diseases. Biomedicine 1980 32: 189 4.
13. Seguchi M, Soejima Y, Tateishi A et al. Mixed connective tissue disease with multiple organ damage: successful treatment with plasmapheresis. Intern Med 2000 39: 1119 22.
14. Lahaye IEE, Rogiers PEM, Nagler JM, Chappel R. Vanishing pulmonary hypertension in mixed connective tissue disease. Clin Rheumatol 1999 18: 45 7.
15. Smith JW, Weinstein R, Hillyer KL. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion 2003 43: 820 2.
16. Matic G, Bosch T, Ramlow W. Background and indications for protein A-based extracorporeal immunoadsorption. Ther Apher 2001 5: 394 403.
17. Braun N, Risler T. Immunoadsorption as a tool for immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther Apher 1999 3: 240 5.
18. Hof D, Cheung K, de Rooij D-JRAM, van den Hoogen FH, Pruijn GJM, van Venrooij WJ, Raats JMH. Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease. Arthritis Res Ther 2005 7: R302 9.
19. Greidinger EL, Zang YJ, Jaimes K et al. A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen. Arthritis Rheum 2006 54: 661 9.
20. Nimelstein SH, Brody S, McShane D, Holman HR. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 1980 59: 239 48.
21. Bettoni L, Geri A, Airo P et al. Systemic sclerosis therapy with Iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumathol 2002 21: 244 50.
22. Humbert M, Cabane J. Successful treatment of systemic sclerosis, digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist Bosentan. Rheumatology 2003 42: 191 3.
23. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulus O et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006 8: R8.